ARTV Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Oragenics, Inc.'s return on equity of -509.23%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 255.65%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 133.07%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Oragenics, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Palatin Technologies's return on equity of --.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 255.65%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Artiva Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Artiva Biotherapeutics, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Palatin Technologies's net income of --. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Rocket Pharmaceuticals, Inc.'s return on equity of -64.31%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 255.65%. On the other hand Rocket Pharmaceuticals, Inc. has an analysts' consensus of $7.65 which suggests that it could grow by 105.65%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Rocket Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Rocket Pharmaceuticals, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rocket Pharmaceuticals, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.886%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Rocket Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Rocket Pharmaceuticals, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Rocket Pharmaceuticals, Inc.'s net income of -$50.3M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Rocket Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Rocket Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 255.65%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3453.3%. Given that Theriva Biologics, Inc. has higher upside potential than Artiva Biotherapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Artiva Biotherapeutics, Inc..

Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.